IDO1 Inhibitor Research 2015~2017

As Recent Progress;



http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.5b00326

Selective P2X7 Antagonists

See For Examples;

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721772/

A more recent study has demonstrated that P2X7 knockout mice show reduced pain sensitivity following both complete Freund’s adjuvant-induced inflammation and partial injury of the sciatic nerve [32].

 

These data were consistent with the mechanistic role of P2X7 receptors in modulating IL-1β release and the ability of IL-1β to alter pain sensitivity in experimental models.

 

It has been shown, for example, that increased IL-1 levels are associated with enhanced nociceptive signaling in a concentration-related fashion [33, 34].

The P2X7 receptor has also been linked with release of the excitatory neurotransmitter glutamate, well-known for its involvement in pain transmission. In hippocampal slices from P2X7 KO mice, ATP-evoked release of [3H]glutamate was virtually absent, in contrast to the robust neurotransmitter release observed with wild-type controls [35].

 

Under electrical stimulation, [3H]glutamate release was also significantly attenuated in the KO animals, although some level of residual release was present. These observations are consistent with results implicating the participation of P2X7 in excitatory amino acid release from murine astrocytes [36].

 

The potential role of P2X7 in modulating glutamate release thus provides an additional rationale for the reduced nociceptive responses of the P2X7 KO mice under chronic inflammation or nerve injury conditions.

 

In view of the participation of P2X7 in the release of IL-1β and glutamate, the localization of P2X7 receptors on glial cells, and the growing appreciation for the role of activated glia in promoting the development and maintenance of pathological pain [37–39], it is tempting to regard the P2X7 receptor as a central player in this neuroimmune interface.

糖化反応阻害剤＝糖トラップ化アミン＝メトフォルミン

 

Ｓｅｅ　Ｆｏｒ　Ｇｏｏｄ　Ｅｘａｍｐｌｅｓ；

 

 

http://ebn.arkray.co.jp/disciplines/glycation/ages-08/

Pleiotropiv Effects of Pitavastatin 2011

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376429/


and More;

Pitavastatin Pleiotropic Study

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387666/

Conclusions

Pitavastatin not only improved atherosis measured by IMT and the sclerosis measured by cIBS values, but also attenuated inflammation of plaques at the same site as measured by max SUV. The present study indicated that pitavastatin had a stronger effect on regression and stabilization of plaques in the thoracic aorta compared with a mild hydrophilic statin.

Go to:

Acknowledgements

This study was funded by a grant from Japan vascular disease research foundation, Kyoto, Japan.

Cilostazol & ROCK 2016

See As Recent Opinions;

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098914/

Simple Radical Metabolic Pathways for Anti-TB Drug & Others

 

Ｒａｄｉｃａｌ　Ｍｅｔａｂｏｌｉｃ　Ｐａｔｈｗａｙｓ

Ｆｏｒ　Ｉｓｏｎｉａｚｉｄ, Ｄｅｌａｍａｎｉｄ and Ｅｐａｌｒｅｓｔａｔ．

This Paper deals with the new radical metabolic patway
for two ant-TB drugs (Isoniazid and Delamanid) and one
ARI (aldose reductase inhibitor).

http://www.pnas.org/content/100/24/13881.full

Ｐｉｔａｖａｓｔａｔｉｎ　Ｗｏｒｋｓ　Ａｓ　ＲｈｏＡ

 

Ｉｎｖｅｒｓｅ　Ａｇｏｎｉｓｔ　Ｂｕｔ　Ｎｏｔ　ＧＰＣＲ１２０　Ｌｉｇａｎｄ．